Polyphor N: Life-changing therapies
| eröffnet am: | 21.04.21 10:24 von: | banditolino |
| neuester Beitrag: | 03.06.21 11:15 von: | banditolino |
| Anzahl Beiträge: | 3 | |
| Leser gesamt: | 6879 | |
| davon Heute: | 2 | |
bewertet mit 0 Sternen |
||
|
|
||
21.04.21 10:24
#1
banditolino
Polyphor N: Life-changing therapies
https://www.polyphor.com/about/
23.05.21 08:47
#2
banditolino
Polyphor: UBS Global Healthcare Virtual Conference
"Polyphor to present at the UBS Global Healthcare Virtual Conference
Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced that the company will present at the UBS Global Healthcare Virtual Conference, taking place May 24 -26, 2021. Gokhan Batur, CEO of Polyphor, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. A replay of the presentation will be available for 30 days following the conclusion of the event."
Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced that the company will present at the UBS Global Healthcare Virtual Conference, taking place May 24 -26, 2021. Gokhan Batur, CEO of Polyphor, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. A replay of the presentation will be available for 30 days following the conclusion of the event."
03.06.21 11:15
#3
banditolino
Polyphor: Balixafortid und Covid-19
vom 01.06.2021:
"EQS-Adhoc: Balixafortide von Polyphor zeigt in präklinischen COVID-19-Studien eine konsistente antivirale und entzündungshemmende Doppelwirkung
Telefonkonferenz zur Diskussion dieser Ergebnisse und der COVID-19 Behandlungslandschaft mit 3 renommierten wissenschaftlichen Experten am 10. Juni um 14.00 Uhr CET"
"EQS-Adhoc: Balixafortide von Polyphor zeigt in präklinischen COVID-19-Studien eine konsistente antivirale und entzündungshemmende Doppelwirkung
Telefonkonferenz zur Diskussion dieser Ergebnisse und der COVID-19 Behandlungslandschaft mit 3 renommierten wissenschaftlichen Experten am 10. Juni um 14.00 Uhr CET"